AFF3 upregulation mediates tamoxifen resistance in breast cancers
Open Access
- 16 October 2018
- journal article
- research article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 37 (1) , 254
Abstract
Although tamoxifen is a highly effective drug for treating estrogen receptor–positive (ER+) breast cancer, nearly all patients with metastasis with initially responsive tumors eventually relapse, and die from acquired drug resistance. Unfortunately, few molecular mediators of tamoxifen resistance have been described. Here, we describe AFF3 (AF4/FMR2 family member 3), which encodes a nuclear protein with transactivation potential that confers tamoxifen resistance and enables estrogen-independent growth. We investigated AFF3 expression in breast cancer cells and in clinical breast cancer specimens with western blot and Real-time PCR. We also examined the effects of AFF3 knockdown and overexpression on breast cancer cells using luciferase, tetrazolium, colony formation, and anchorage-independent growth assays in vitro and with nude mouse xenografting in vivo. AFF3 was overexpressed in tamoxifen-resistant tumors. AFF3 overexpression in breast cancer cells resulted in tamoxifen resistance, whereas RNA interference–mediated gene knockdown reversed this phenotype. Furthermore, AFF3 upregulation led to estrogen-independent growth in the xenograft assays. Mechanistic investigations revealed that AFF3 overexpression activated the ER signaling pathway and transcriptionally upregulated a subset of ER-regulated genes. Clinical analysis showed that increased AFF3 expression in ER+ breast tumors was associated with worse overall survival. These studies establish AFF3 as a key mediator of estrogen-independent growth and tamoxifen resistance and as a potential novel diagnostic and therapeutic target.Keywords
This publication has 34 references indexed in Scilit:
- Acquired Resistance to Tamoxifen Is Associated with Loss of the Type I Insulin-like Growth Factor Receptor: Implications for Breast Cancer TreatmentCancer Research, 2012
- The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathwayProceedings of the National Academy of Sciences, 2011
- Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistanceOncogene, 2011
- Tamoxifen-stimulated growth of breast cancer due to p21 lossProceedings of the National Academy of Sciences, 2008
- Tamoxifen—What Next?The Oncologist, 2004
- Fusion of an AF4-related gene, LAF4, to MLL in childhood acute lymphoblastic leukemia with t(2;11)(q11;q23)Oncogene, 2003
- A novel infant acute lymphoblastic leukemia cell line with MLL-AF5q31 fusion transcriptLeukemia, 2002
- LAF4, an AF4‐related gene, is fused to MLL in infant acute lymphoblastic leukemiaGenes, Chromosomes and Cancer, 2002
- Molecular Determinants for the Tissue Specificity of SERMsScience, 2002
- The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 geneCell, 1992